SE9703206L - Oral komposition innehållande olanzapin och förfarande för framställning därav - Google Patents

Oral komposition innehållande olanzapin och förfarande för framställning därav

Info

Publication number
SE9703206L
SE9703206L SE9703206A SE9703206A SE9703206L SE 9703206 L SE9703206 L SE 9703206L SE 9703206 A SE9703206 A SE 9703206A SE 9703206 A SE9703206 A SE 9703206A SE 9703206 L SE9703206 L SE 9703206L
Authority
SE
Sweden
Prior art keywords
formulation
olanzapine
solid oral
preparation
composition containing
Prior art date
Application number
SE9703206A
Other languages
English (en)
Swedish (sv)
Other versions
SE9703206D0 (sv
Inventor
George Randall Cochran
Tommy Clifford Morris
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23624847&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE9703206(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SE9703206D0 publication Critical patent/SE9703206D0/xx
Publication of SE9703206L publication Critical patent/SE9703206L/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SE9703206A 1995-03-24 1997-09-05 Oral komposition innehållande olanzapin och förfarande för framställning därav SE9703206L (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41046595A 1995-03-24 1995-03-24
PCT/US1996/003918 WO1996029995A1 (en) 1995-03-24 1996-03-22 Oral 2-methyl-thieno-benzodiazepine formulation

Publications (2)

Publication Number Publication Date
SE9703206D0 SE9703206D0 (sv) 1997-09-05
SE9703206L true SE9703206L (sv) 1997-09-05

Family

ID=23624847

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9703206A SE9703206L (sv) 1995-03-24 1997-09-05 Oral komposition innehållande olanzapin och förfarande för framställning därav

Country Status (46)

Country Link
US (4) US5919485A (cs)
EP (2) EP1093815B1 (cs)
JP (1) JPH11502848A (cs)
KR (1) KR100408172B1 (cs)
CN (1) CN1178662C (cs)
AP (1) AP679A (cs)
AR (2) AR001405A1 (cs)
AT (3) ATE206924T1 (cs)
AU (1) AU696601B2 (cs)
BG (1) BG62594B1 (cs)
BR (1) BR9607791A (cs)
CA (1) CA2216372C (cs)
CH (1) CH691217A5 (cs)
CO (1) CO4700474A1 (cs)
CR (1) CR5278A (cs)
CZ (1) CZ296007B6 (cs)
DE (3) DE69634053T2 (cs)
DK (3) DK1093815T3 (cs)
EA (1) EA000938B1 (cs)
EE (1) EE03551B1 (cs)
EG (1) EG24077A (cs)
ES (2) ES2164837T3 (cs)
FI (1) FI973749A7 (cs)
GB (1) GB2313783B (cs)
HU (1) HU225269B1 (cs)
IL (1) IL117611A (cs)
IS (1) IS1903B (cs)
LT (1) LT4350B (cs)
LU (1) LU90115B1 (cs)
LV (1) LV11983B (cs)
MY (1) MY113440A (cs)
NO (1) NO320388B1 (cs)
NZ (1) NZ306111A (cs)
OA (1) OA10511A (cs)
PE (1) PE44997A1 (cs)
PL (1) PL188316B1 (cs)
PT (2) PT1093815E (cs)
RO (1) RO118370B1 (cs)
SE (1) SE9703206L (cs)
SI (3) SI9620041A (cs)
SK (1) SK283745B6 (cs)
TR (1) TR199701018T1 (cs)
TW (1) TW426526B (cs)
UA (1) UA44766C2 (cs)
WO (1) WO1996029995A1 (cs)
ZA (1) ZA962338B (cs)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
CZ98899A3 (cs) * 1996-09-24 1999-12-15 Eli Lilly And Company Složení potahovaných částic
US20020035071A1 (en) * 1997-07-08 2002-03-21 Josef Pitha Mimicking the metabolic effects of caloric restriction by administration of glucose antimetabolites
US8563522B2 (en) * 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
US20060116330A1 (en) * 1997-07-08 2006-06-01 The Iams Company Methods of mimicking the metabolic effects of caloric restriction by administration of mannoheptulose
US6617321B2 (en) 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
US6348458B1 (en) 1999-12-28 2002-02-19 U & I Pharmaceuticals Ltd. Polymorphic forms of olanzapine
AU779452B2 (en) * 1999-12-28 2005-01-27 Cipla Limited New polymorphic forms of olanzapine
US7022698B2 (en) 1999-12-28 2006-04-04 U & I Pharmaceuticals, Ltd. Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
US6740753B2 (en) 2001-01-04 2004-05-25 Geneva Pharmaceuticals, Inc. Olanzapine crystal modification
US20030070584A1 (en) 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
US20030072729A1 (en) * 2001-05-15 2003-04-17 Christopher Szymczak Simethicone as weight gain enhancer
US20030072731A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing starch or dextrin
US8309118B2 (en) 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
GB0203061D0 (en) * 2002-02-08 2002-03-27 Novartis Ag Organic compounds
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
WO2003086361A1 (en) * 2002-04-18 2003-10-23 Dr. Reddy's Laboratories Ltd. Rapidly dispersing solid oral compositions
AU2003237305A1 (en) 2002-05-31 2003-12-19 Geneva Pharmaceuticals, Inc. Process of preparation of olanzapine form i
SI21270A (sl) * 2002-07-15 2004-02-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Kristalne oblike olanzapina in postopki za njihovo pripravo
US7429619B2 (en) 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
US7029112B2 (en) 2002-08-05 2006-04-18 Mars, Incorporated Ink-jet printing on surface modified edibles and products made
US8168170B2 (en) * 2002-10-03 2012-05-01 The Procter And Gamble Company Compositions having an inner core and at least three surrounding layers
PL202856B1 (pl) * 2002-12-20 2009-07-31 Adamed Spo & Lstrok Ka Z Ogran Sposób otrzymywania farmaceutycznie czystej polimorficznej postaci I olanzapiny
WO2005009407A2 (en) * 2003-07-29 2005-02-03 Ranbaxy Laboratories Limited Oral pharmaceutical formulations of olanzapine
CN1863517B (zh) * 2003-10-07 2011-08-03 安壮奇制药公司 快速崩解制剂
JP2007511605A (ja) * 2003-11-18 2007-05-10 スリーエム イノベイティブ プロパティズ カンパニー オランザピン含有経皮薬物送達組成物
US8894991B2 (en) * 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
US20050152884A1 (en) * 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US8877178B2 (en) * 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US20050158294A1 (en) * 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
ES2253091B1 (es) * 2004-07-27 2007-02-01 Inke, S.A. Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo.
PT1838716E (pt) 2005-01-05 2011-07-15 Lilly Co Eli Di-hidrato de pamoato de olanzapina
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
PL385455A1 (pl) * 2005-04-22 2008-11-24 Teva Pharmaceuticals Usa,Inc. Doustna rozpadająca się farmaceutyczna tabletka preparatów olanzapiny
CA2609617C (en) * 2005-05-31 2014-07-08 The Iams Company Feline probiotic lactobacilli
CA2607949C (en) * 2005-05-31 2012-09-25 Thomas William-Maxwell Boileau Feline probiotic bifidobacteria
US20070014847A1 (en) * 2005-07-05 2007-01-18 Ahmed Salah U Coated capsules and methods of making and using the same
EP1909777A2 (en) * 2005-07-22 2008-04-16 Myriad Genetics, Inc. High drug load formulations and dosage forms
WO2007049304A2 (en) * 2005-10-27 2007-05-03 Jubilant Organosys Limited Stable coated pharmaceutical formulation of olanzapine and process for preparing the same
GB0522474D0 (en) 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
GB0522473D0 (en) * 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
ES2279715B1 (es) * 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.
US7834176B2 (en) 2006-01-26 2010-11-16 Sandoz Ag Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
WO2007134845A2 (en) * 2006-05-18 2007-11-29 Synthon B.V. Olanzapine pharmaceutical composition
WO2008004033A1 (en) * 2006-07-05 2008-01-10 Bilim Ilac Sanayii Ve Ticaret A.S. A stable olanzapine formulation with antioxidants
CL2007002807A1 (es) * 2006-09-29 2008-04-11 Synthon Bv Composicion farmaceutica en estado solido que comprende olanzapina o una sal farmaceuticamente aceptable de la misma y lactosa anhidra; tableta farmaceutica oral; procedimiento de preparacion de dicha tableta, util en el tratamiento de la esquizofren
CA2673465A1 (en) 2007-02-01 2008-08-07 The Iams Company Method for decreasing inflammation and stress in a mammal
US8722133B2 (en) * 2008-01-31 2014-05-13 Kyorin Pharmaceutical Co., Ltd. Method for production of orally rapidly disintegrating tablet comprising imidafenacin as active ingredient
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US8505322B2 (en) * 2009-03-25 2013-08-13 Pax Scientific, Inc. Battery cooling
US20110048048A1 (en) * 2009-03-25 2011-03-03 Thomas Gielda Personal Cooling System
AU2010229821A1 (en) * 2009-03-25 2011-11-17 Caitin, Inc. Supersonic cooling system
US20110051549A1 (en) * 2009-07-25 2011-03-03 Kristian Debus Nucleation Ring for a Central Insert
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
US8365540B2 (en) * 2009-09-04 2013-02-05 Pax Scientific, Inc. System and method for heat transfer
WO2012153347A2 (en) 2011-05-04 2012-11-15 Zentiva K.S. Oral pharmaceutical composition of olanzapine form 1
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
US9517212B1 (en) * 2012-11-15 2016-12-13 Chandra Zaveri Medicated adhesive pad arrangement
CN103919782B (zh) * 2013-01-15 2016-12-28 天津药物研究院有限公司 一种含有奥氮平的药物组合物及其制备方法
PL3043778T3 (pl) * 2013-09-13 2018-04-30 Bayer Pharma Aktiengesellschaft Kompozycje farmaceutyczne zawierające refametinib
CN107007559B (zh) * 2017-04-21 2020-05-15 浙江京新药业股份有限公司 一种稳定的口服药物组合物及其制备方法
KR102646865B1 (ko) * 2017-06-02 2024-03-11 엑스에리스 파머수티클스, 인크. 침전 방지 저분자 약물 제제
CN113143878A (zh) * 2021-03-19 2021-07-23 杭州新诺华医药有限公司 奥氮平组合物及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115568A (en) * 1974-11-26 1978-09-19 Lilly Industries Limited Thieno[3,2-b]-[1,5]benzodiazepines
US4172831A (en) * 1974-11-26 1979-10-30 Lilly Industries Limited Thieno-benzodiazepines
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US4820522A (en) * 1987-07-27 1989-04-11 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
ZA922776B (en) * 1991-04-29 1993-10-15 Lilly Co Eli Pharmaceutical compounds
JPH05194225A (ja) * 1991-11-07 1993-08-03 Yoshitomi Pharmaceut Ind Ltd 安定化された抗潰瘍剤含有製剤
EP0582368B1 (en) * 1992-05-29 2001-01-24 Eli Lilly And Company Limited Thienobenzodiazepine derivatives for treatment of CNS disorders
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
US5696115A (en) * 1995-04-21 1997-12-09 Eli Lilly And Company Method for treating nicotine withdrawal

Also Published As

Publication number Publication date
ZA962338B (en) 1997-09-22
DK1093815T3 (da) 2005-04-25
FI973749A0 (fi) 1997-09-22
EA000938B1 (ru) 2000-06-26
LT97149A (lt) 1998-01-26
PT1093815E (pt) 2005-03-31
BG62594B1 (bg) 2000-03-31
WO1996029995A1 (en) 1996-10-03
EP1093815A1 (en) 2001-04-25
AR002720A1 (es) 1998-04-29
UA44766C2 (uk) 2002-03-15
DE19681287T1 (de) 1998-03-19
PT733367E (pt) 2002-03-28
CN1178662C (zh) 2004-12-08
CR5278A (es) 1996-07-04
ES2232379T3 (es) 2005-06-01
CO4700474A1 (es) 1998-12-29
DK173323B1 (da) 2000-07-24
KR19980703189A (ko) 1998-10-15
SI1093815T1 (en) 2005-06-30
AR001405A1 (es) 1997-10-22
AU5428096A (en) 1996-10-16
DK109097A (da) 1997-11-12
EG24077A (en) 2008-05-11
HUP9800410A3 (en) 2000-01-28
EE03551B1 (et) 2001-12-17
NO974363L (no) 1997-11-17
NO974363D0 (no) 1997-09-22
AU696601B2 (en) 1998-09-17
MY113440A (en) 2002-02-28
FI973749L (fi) 1997-09-22
EP1093815B1 (en) 2004-12-15
SE9703206D0 (sv) 1997-09-05
JPH11502848A (ja) 1999-03-09
PL322579A1 (en) 1998-02-02
SK128297A3 (en) 1998-03-04
LV11983A (lv) 1998-03-20
NO320388B1 (no) 2005-11-28
HUP9800410A2 (hu) 1998-07-28
BG101901A (bg) 1998-10-30
PL188316B1 (pl) 2005-01-31
CN1179102A (zh) 1998-04-15
GB2313783B (en) 1998-11-18
CZ300197A3 (en) 1997-12-17
SK283745B6 (sk) 2003-12-02
EP0733367A1 (en) 1996-09-25
KR100408172B1 (ko) 2004-02-18
IL117611A (en) 2002-05-23
GB2313783A (en) 1997-12-10
AT405606B (de) 1999-10-25
TR199701018T1 (xx) 1998-01-21
LT4350B (lt) 1998-05-25
ES2164837T3 (es) 2002-03-01
BR9607791A (pt) 1998-07-07
DE69615887T2 (de) 2002-04-11
HU225269B1 (en) 2006-08-28
CA2216372C (en) 2007-11-20
MX9707186A (es) 1997-11-29
US7229643B2 (en) 2007-06-12
IL117611A0 (en) 1996-07-23
LU90115B1 (fr) 1997-09-10
US6190698B1 (en) 2001-02-20
PE44997A1 (es) 1997-10-23
IS1903B (is) 2003-11-20
DE69634053D1 (de) 2005-01-20
CZ296007B6 (cs) 2005-12-14
US20010018071A1 (en) 2001-08-30
ATE284695T1 (de) 2005-01-15
AP9701064A0 (en) 1997-10-31
NZ306111A (en) 1999-02-25
US5919485A (en) 1999-07-06
SI0733367T1 (en) 2002-06-30
TW426526B (en) 2001-03-21
DE69634053T2 (de) 2005-12-22
CA2216372A1 (en) 1996-10-03
OA10511A (en) 2002-04-24
FI973749A7 (fi) 1997-09-22
CH691217A5 (de) 2001-05-31
IS4565A (is) 1997-09-22
RO118370B1 (ro) 2003-05-30
EP0733367B1 (en) 2001-10-17
SI9620041A (sl) 1998-06-30
ATA902296A (de) 1999-02-15
GB9719817D0 (en) 1997-11-19
DE69615887D1 (de) 2001-11-22
LV11983B (en) 1998-07-20
ATE206924T1 (de) 2001-11-15
EA199700260A1 (ru) 1998-02-26
US20050085462A1 (en) 2005-04-21
DK0733367T3 (da) 2001-11-26
AP679A (en) 1998-09-28
US6780433B2 (en) 2004-08-24
EE9700328A (et) 1998-06-15

Similar Documents

Publication Publication Date Title
SE9703206L (sv) Oral komposition innehållande olanzapin och förfarande för framställning därav
AU613663B2 (en) Sustained release etodolac
KR920702618A (ko) 약제학적 제형
US4789549A (en) Sustained release dosage forms
NZ336251A (en) Composition comprising a core layer (active ingredient, hydroxypropyl cellulose and microcrystalline cellulose), an inner layer (such as hydroxypropylmethyl cellulose, polyvinyl pyrolidore and lubricants; magnesium stearate or talc), an outer layer (hydroxypropylmethyl and hydroxypropyl cellulose)
DE68920578D1 (de) Verschiedenartige Zelluloseether enthaltende, oral verabreichbare Arzneimittelformen mit gesteuerter Wirkstofffreigabe.
IL142474A0 (en) Pharmaceutical formulation comprising omeprazole
SE8406081L (sv) Sett och komposition for framstellning av farmaceutiska preparat for oral administrering och med kontrollerad langtidsverkan
EP2087889A3 (en) Controlled release oral tablet having a unitary core
PT923934E (pt) Formulacao de matriz de libertacao modificada de cefaclor e cefalexina
CA2264238A1 (fr) Forme galenique a liberation prolongee de milnacipran
EE200100505A (et) Modifitseeritud tärklise kasutamine hüdrofiilses kontrollitud vabanemisega preparaadis, hüdrofiilnekontrollitud vabanemisega preparaat, selle valmistamismeetod ja kasutamine ning ravimvorm
IE970588A1 (en) Controlled release pharmaceutical compositions containing tiagabine
YU60899A (sh) Farmaceutska formulacija omeprazola
MX9804008A (es) Formulaciones farmaceuticas.
KR910011243A (ko) 서방성 약제 용량 단위
EP0382077A3 (de) Diarylsubstituierte heterocyclische Verbindung, ihre Herstellung und Arzneimittel und Kosmetika daraus
AR016827A1 (es) PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA
NO931859L (no) Blanding for kontrollert frigjoering av en aktiv bestanddel
KR20010062478A (ko) 경구투여후 트리메트아지딘의 지속적 방출을 가능케 하는매트릭스 정제
CA2005987A1 (en) Therapeutically active substituted benzimidazole and process for its preparation
EE9600202A (et) Toimeaine pärsitud vabanemisega karbamasepiini ravimvorm
DE60117712D1 (de) Pharmazeutische zusammensetzung für die kontrollierte freisetzung eines beta-lactam-antibiotikums
CA2433915A1 (en) Improved controlled release oral dosage form
ES2170168T3 (es) Composiciones recubiertas entericamente de derivados de 1,5-benzodiacepina con actividad antagonista o agonista de cck.

Legal Events

Date Code Title Description
NAV Patent application has lapsed